Results 31 to 40 of about 1,483,959 (183)

Thrombosis in Myeloproliferative Neoplasms With JAK2V617F Mutation [PDF]

open access: yesClinical and Applied Thrombosis/Hemostasis, 2012
Myeloproliferative neoplasms (MPNs) are clonal hematopoietic stem cell disorders and are characterized by advanced proliferation and survival advantage. These abnormalities are considered to derive from the point mutation in exon 14 of the Janus kinase 2 genes (JAK2 V617F).
Tiantian, Sun, Lei, Zhang
openaire   +2 more sources

Concomitant occurrence of BCR-ABL and JAK2V617F mutation [PDF]

open access: yesBlood, 2011
To the editor: In a recent issue of the journal, Makishima et al[1][1] reported on the occurrence of mutations typically associated with Philadelphia-chromosome (Ph1) negative myeloproliferative (MPN)/ myelodysplastic neoplasms in 54 patients with typical chronic myelogenous leukemia (CML ...
PIERI, LISA   +8 more
openaire   +5 more sources

JAK2/STAT5 Pathway Mutation Frequencies in South African BCR/ABL Negative MPN Patients

open access: yesHematology/Oncology and Stem Cell Therapy, 2023
Background: Mutations in JAK2/STAT5 proliferation pathway genes are key in the diagnosis of myeloproliferative neoplasms (MPNBCR/ABLneg), with JAK2V617F being found in 50-97% of MPNBCR/ABLneg subtypes.
Karen L. Shires   +4 more
doaj   +1 more source

Sequential Development of JAK2V617F Mutation and BCR-ABL1 Fusion in Individual Patients With Myeloproliferative Neoplasms: A Linear Clonal Evolution or Parallel Clonal Competition?

open access: yesArchives of Pathology & Laboratory Medicine, 2021
CONTEXT.— Concomitant BCR-ABL1 and JAK2V617F in myeloproliferative neoplasms (MPNs) is rare, and its pathogenesis and clinical significance are unclear.
Yue Zhao   +6 more
semanticscholar   +1 more source

Impact of JAK2V617F Mutational Status on Phenotypic Features in Essential Thrombocythemia and Primary Myelofibrosis

open access: yesTurkish Journal of Hematology, 2016
INTRODUCTION: The JAK2V617F mutation is present in the majority of patients with essential thrombocythemia (ET) and primary myelofibrosis (PMF). The impact of this mutation on disease phenotype in ET and PMF is still a matter of discussion.
İpek Yonal   +6 more
doaj   +1 more source

Association of High-Altitude Polycythemia with JAK2V617F Mutation in Pakistani Population. [PDF]

open access: yesIndian J Hematol Blood Transfus
To assessthe prevalence of the JAK2V617F mutation in polycythemia patients living at high altitude. This was a cross-sectional study, conducted at the National Institute of Blood Diseasesand Bone Marrow Transplantation (NIBD-BMT), KarachifromJuly 2022 to July 2023.
Fayyaz F   +6 more
europepmc   +4 more sources

JAK2V617F somatic mutation in the general population: myeloproliferative neoplasm development and progression rate

open access: yesHaematologica, 2014
Clinical significance of the JAK2V617F mutation in patients with a myeloproliferative neoplasm has been the target of intensive research in recent years. However, there is considerably uncertainty about prognosis in JAK2V617F positive individuals without
Camilla Nielsen   +4 more
doaj   +1 more source

Detection of JAK2V617F tyrosine kinase mutation and estimation of serum erythropoietin in blood donors who have high hematocrit

open access: yesمجلة كلية الطب, 2015
Background: JAK2V617F mutation is the most prevalent molecular abnormality in myeloproliferative neoplasms (MPNs) and has become a valuable marker for diagnosis of MPNs. Almost all patients with polycythemia vera (PV) have this acquired mutation. However,
Haythem A. AL-Rubaie   +2 more
doaj   +1 more source

Visual screening for JAK2V617F mutation by a disposable dipstick

open access: yesAnalytical and Bioanalytical Chemistry, 2010
During the last 5 years, it was discovered that the JAK2V617F somatic mutation is present in virtually all patients with polycythemia vera and a large proportion of patients with essential thrombocythemia, primary myelofibrosis, and refractory anemia with ring sideroblasts and thrombocytosis.
Konstantou, J.K.   +6 more
openaire   +3 more sources

Exposure-Response Analyses of Ropeginterferon Alfa-2b in Essential Thrombocythemia. [PDF]

open access: yesJ Clin Pharmacol
Abstract Ropeginterferon alfa‐2b is a new‐generation interferon therapy for the treatment of myeloproliferative neoplasms (MPNs), including essential thrombocythemia (ET). This investigation was designed to characterize its population pharmacokinetics–pharmacodynamics (PopPK‐PD) and delineate exposure–response (E‐R) relationships in ET. A population PK
Qin A   +20 more
europepmc   +2 more sources

Home - About - Disclaimer - Privacy